The concept of oligometastatic disease in gastric cancer: reality or fiction?

References

• 1. Wang F-H, Shen L, Li J et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun. 39(1), 10 (2019).
  Google Scholar
• 2. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. In: Cancer Epidemiology (Volume 472). Verma M (Ed.). Humana Press, NJ, USA, 467–477 (2009).
  Google Scholar
• 3. Yang D, Hendifar A, Lenz C et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J. Gastrointest. Oncol. 2(2), 77–84 (2011).
  Medline CASGoogle Scholar
• 4. Assi T, El Rassy E, Khazzaka A et al. Characteristics of gastric cancer in Lebanon: a descriptive study from a single institutional experience. J. Gastrointest. Cancer 49(1), 21–24 (2018).
  MedlineGoogle Scholar
• 5. Jin P, Ji X, Tian Y. Surgical management of oligometastatic disease in gastric cancer. Clin. Res. Hepatol. Gastroenterol. 44(5), 638–645 (2020).
  MedlineGoogle Scholar
• 6. Ministrini S, Solaini L, Cipollari C et al. Surgical treatment of hepatic metastases from gastric cancer. Updat. Surg. 70(2), 273–278 (2018).
  MedlineGoogle Scholar
• 7. Gadde R, Tamariz L, Hanna M et al. Metastatic gastric cancer (MGC) patients: can we improve survival by metastasectomy? A systematic review and meta-analysis: Metastatic Gastric Cancer (MGC) Patients. J. Surg. Oncol. 112(1), 38–45 (2015).
  MedlineGoogle Scholar
• 8. Hellman S, Weichselbaum RR. Oligometastases. J. Clin. Oncol. 13(1), 8–10 (1995).
  Medline CASGoogle Scholar
• 9. Van den Begin R, Engels B, Gevaert T et al. Impact of inadequate respiratory motion management in SBRT for oligometastatic colorectal cancer. Radiother. Oncol. 113(2), 235–239 (2014).
  MedlineGoogle Scholar
• 10. Lussier YA, Xing HR, Salama JK et al. MicroRNA expression characterizes oligometastasis(es). PLoS ONE 6(12), e28650 (2011).
  Medline CASGoogle Scholar
• 11. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm. Med. 2012, 1–5 (2012).
  Google Scholar
• 12. Mönig S, van Hootegem S, Chevallay M, Wijnhoven BPL. The role of surgery in advanced disease for esophageal and junctional cancer. Best Pract. Res. Clin. Gastroenterol. 36–37, 91–96 (2018).
  MedlineGoogle Scholar
• 13. Al-Batran S-E, Homann N, Pauligk C et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 Trial. JAMA Oncol. 3(9), 1237 (2017).
  MedlineGoogle Scholar
• 14. Chiapponi C, Berlth F, Plum PS et al. Oligometastatic disease in upper gastrointestinal cancer – how to proceed? Visc. Med. 33(1), 31–34 (2017).
  MedlineGoogle Scholar
• 15. Jung J, Jung Y, Bang EJ et al. Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling. Ann. Surg. Oncol. 21(S4), 736–742 (2014).
  Google Scholar
• 16. Polom K, Böger C, Smyth E et al. Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. Eur. J. Surg. Oncol. 44(5), 626–631 (2018).
  MedlineGoogle Scholar
• 17. Ramos RF, Scalon FM, Scalon MM, Dias DI. Staging laparoscopy in gastric cancer to detect peritoneal metastases: a systematic review and meta-analysis. Eur. J. Surg. Oncol. 42(9), 1315–1321 (2016).
  Medline CASGoogle Scholar
• 18. deSouza NM, Liu Y, Chiti A et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer Imaging Group. Eur. J. Cancer 91, 153–163 (2018).
  MedlineGoogle Scholar
• 19. Rudloff U, Langan RC, Mullinax JE et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial: gastric cancer multimodal therapy. J. Surg. Oncol. 110(3), 275–284 (2014).
  MedlineGoogle Scholar
• 20. Ito H, Takemura N, Ono Y et al. Gastric cancer liver metastasis: optimal management for oligo-metastatic disease. J. Clin. Oncol. 37(Suppl. 4), 136–136 (2019).
  Google Scholar
• 21. Grimes N, Devlin J, Dunne DFJ, Poston G, Fenwick S, Malik H. The role of hepatectomy in the management of metastatic gastric adenocarcinoma: a systematic review. Surg. Oncol. 23(4), 177–185 (2014).
  MedlineGoogle Scholar
• 22. Jung MK, Ott K, Chevallay M, Mönig SP. Therapieoptionen beim oligometastasierten Magenkarzinom. Chir. 92(6), 515–521 (2021).
  MedlineGoogle Scholar
• 23. Al-Batran S-E, Goetze TO, Mueller DW et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17(1), 893 (2017).
  MedlineGoogle Scholar
• 24. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 24(1), 1–21 (2021).
  MedlineGoogle Scholar